Why the study?
Does the Ki-67 index predict overall survival in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy?
Does the Ki-67 index predict overall survival in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy?
The Ki-67 index remains an important independent prognostic marker for overall survival in advanced-stage mantle cell lymphoma patients treated with anti-CD20 therapy.
This is the authors' abstract. We don't add key points for this paper.
Clinical outcome of mantle cell lymphoma (MCL) is highly heterogeneous. Tumor cell proliferation as assessed by the Ki-67 index has been shown to yield prognostic information on MCL in many studies using heterogeneously treated patient cohorts. The prognostic value of the Ki-67 index in patients treated with anti-CD20 therapy has not been studied so far. We analyzed the Ki-67 index at primary diagnosis in 249 advanced-stage MCL patients treated within randomized trials. Ki-67 showed high prognostic relevance for overall survival (relative risk 1.27 for 10% higher Ki-67, P < .001), also independently from clinical prognostic factors. The 3 groups with different Ki-67 index of less than 10%, 10% to less than 30%, and 30% or more showed significantly different overall survival in patients treated with CHOP (P = .001) as well as in patients treated with CHOP in combination with anti-CD20 therapy (R-CHOP, P = .013). Thus, the Ki-67 index remains an important prognostic marker in the era of anti-CD20 therapy. The Euro-pean MCL study is registered at www.ClinicalTrials.gov as #NCT00016887.
Answers are grounded in this paper and cite their sources.
Ki-67 may refine prognostication in advanced MCL on anti-CD20 therapy; extends independent value but leaves open therapeutic implications.
No takes yet. Share an insight, caveat, or question.
Determann et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: